Although much focus has been placed on the use of opioids for chronic pain, unused opioids prescribed for acute surgical pain are an important source of opioid diversion and abuse. Few studies have looked into the prescribing patterns for pediatric patients undergoing acute surgical intervention. This study describes the opioid prescribing habits of pediatric surgeons for acute postoperative pain and evaluates the quantity of unused opioids after the conclusion of acute surgical pain.
METHODS:
A single-institution retrospective review of all outpatient surgeries from June 2016 to April 2018 was performed. Patients were given a patient-reported outcome measure tracking their daily maximal level of pain postoperatively and the doses of opioid used. With data from chart reviews and pharmacy dispensing logs, we determined the amount of opioids prescribed and pills remaining.
RESULTS:
In total, 89% of all pills prescribed went unused (4,744 doses of opioid prescribed with 4,232 unused). An average of 17.1 doses of opioid pills were prescribed to postsurgical patients, and on average, 15.1 doses went unused. We found that 52% of the patients in our study did not use any opioid medications postoperatively. For patients who used opioids, an average of 3.8 doses were used, with 90% of patients using 9 doses or less. Compared to patients who had soft tissue surgery, patients who underwent bone surgery were more likely to use opioids although the number of doses used was the same as soft tissue surgery patients. However, bone surgery patients were prescribed more opioids and thus had more opioids leftover.
CONCLUSION:
Pediatric surgeons often prescribe more opioids than necessary to treat acute surgical pain, with orthopedic surgeons prescribing significantly higher doses of opioid medications. The opioid excess may contribute to the epidemic of nonmedical use of prescription opioids if disposed of improperly by patients and their families. More research and education are necessary to optimize postoperative pain medication prescribing habits. There remains a lack of data and therefore consensus supporting this perceived risk, leading to variations in practice with significant psychosocial implications. With an ever increasing number of gender-affirming surgeries (GASs) performed annually, we sought to examine the risks and incidence correlated with CSHT and elective surgery.
Venothromboembolism Risk and Hormone Therapy in the Elective Surgery Patient

METHODS:
A retrospective chart review was performed of all patients who underwent GAS at a single-center institution between 2016 and 2019. Demographic information, preoperative assessment including CAPRINI scores, CSHT regimen/duration, practice of preoperative risk reduction, postoperative VTE prophylaxis management, surgery type, and outcomes were examined.
RESULTS:
Between 2016 and 2018, 850 GAS cases were identified among 706 patients, 249 transmasculine procedures, and 601 transfeminine procedures. Transmasculine surgeries included 92 hysterectomies, 92 mastectomies, 26 metoidioplasties, and 31 phalloplasties. Transfeminine surgeries included 309 primary vaginoplasties, 75 revisional vaginoplasties, 93 breast augmentations, and 48 facial feminization surgeries. The most common CSHT regimen was testosterone intramuscular injection for transmen and oral estradiol with spironolactone for transwomen. Mean postoperative follow-up was 309 days. The mean calculated 2005 CAPRINI score was 3. Subset analysis revealed that 229 cases were performed without CSHT held before surgery and 708 cases were performed with CSHT held 1 week before surgery. All patients had the same postoperative VTE prophylaxis regimen with heparin SQ started on the morning of postoperative day 1. One patient was
